$535 Million is the total value of Opaleye Management Inc.'s 48 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 43.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BBIO | Sell | BRIDGEBIO PHARMA INC | $23,974,000 | -24.0% | 511,500 | -1.1% | 4.48% | -14.5% |
| ETON | Sell | ETON PHARMACEUTICALS INC | $15,564,000 | -46.9% | 3,088,100 | -16.4% | 2.91% | -40.3% |
| FBIO | Sell | FORTRESS BIOTECH INC | $12,075,000 | -12.7% | 3,750,000 | -3.2% | 2.26% | -1.9% |
| MGNX | Sell | MACROGENICS INC | $9,674,000 | -37.7% | 462,000 | -20.1% | 1.81% | -29.9% |
| PCVX | Sell | VAXCYTE INC | $8,966,000 | +11.3% | 353,400 | -1.2% | 1.68% | +25.2% |
| XOMA | Sell | XOMA CORP DEL | $8,374,000 | -28.3% | 338,350 | -1.5% | 1.56% | -19.4% |
| NLTX | Sell | NEOLEUKIN THERAPEUTICS INC | $7,572,000 | -29.0% | 1,047,300 | -9.4% | 1.41% | -20.2% |
| ADMS | Sell | ADAMAS PHARMACEUTICALS INC | $7,169,000 | -18.7% | 1,460,000 | -12.6% | 1.34% | -8.6% |
| AFIB | Sell | ACUTUS MEDICAL INC | $5,216,000 | -48.8% | 590,000 | -1.7% | 0.97% | -42.4% |
| AVEO | Sell | AVEO BIOSCIENCES INC | $2,816,000 | -34.0% | 455,600 | -29.6% | 0.53% | -25.7% |
| SIOX | Sell | SIO GENE THERAPIES INC | $2,072,000 | -60.6% | 955,000 | -52.2% | 0.39% | -55.7% |
| LPTX | Sell | LEAP THERAPEUTICS INC | $1,909,000 | +115.5% | 476,000 | -11.9% | 0.36% | +142.9% |
| Sell | APTOSE BIOSCIENCES INC | $1,197,000 | -63.2% | 549,000 | -44.0% | 0.22% | -58.5% | |
| CDTX | Exit | CIDARA THERAPEUTICS INC | $0 | – | -73,351 | -100.0% | -0.02% | – |
| CFRX | Exit | CONTRAFECT CORP | $0 | – | -57,900 | -100.0% | -0.04% | – |
| PHVS | Exit | PHARVARIS NV | $0 | – | -79,837 | -100.0% | -0.25% | – |
| CRDF | Exit | CARDIFF ONCOLOGY INC | $0 | – | -463,000 | -100.0% | -0.51% | – |
| KZR | Exit | KEZAR LIFE SCIENCES INC | $0 | – | -697,800 | -100.0% | -0.63% | – |
| LUMO | Exit | LUMOS PHARMA INC | $0 | – | -382,000 | -100.0% | -0.63% | – |
| CERC | Exit | CERECOR INC | $0 | – | -1,567,494 | -100.0% | -0.85% | – |
| CMLF | Exit | CM LIFE SCIENCES INC | $0 | – | -373,828 | -100.0% | -0.87% | – |
| MCRB | Exit | SERES THERAPEUTICS INC | $0 | – | -250,000 | -100.0% | -0.99% | – |
| EPIX | Exit | ESSA PHARMA INC | $0 | – | -284,050 | -100.0% | -1.35% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-11-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CODEXIS INC | 39 | Q3 2023 | 10.9% |
| CHIMERIX INC | 31 | Q3 2022 | 16.4% |
| XOMA CORP DEL | 27 | Q3 2023 | 3.6% |
| FIBROGEN INC | 26 | Q1 2021 | 6.8% |
| BIOLINERX LTD (Does not reflect a reverse stock split effectuated after June 30, 2019) | 26 | Q1 2020 | 2.4% |
| OCULAR THERAPEUTIX INC | 24 | Q3 2023 | 17.6% |
| AXOGEN INC | 20 | Q4 2019 | 18.7% |
| ETON PHARMACEUTICALS INC | 20 | Q3 2023 | 5.6% |
| AMARIN CORP PLC | 20 | Q4 2020 | 6.6% |
| IMPRIMIS PHARMACEUTICALS INC | 19 | Q1 2020 | 5.9% |
View Opaleye Management Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CHIMERIX INCSold out | February 13, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc. | January 23, 2023 | 1,560,000 | 3.6% |
| TELA Bio, Inc. | June 10, 2022 | 1,557,500 | 10.7% |
| Gemini Therapeutics, Inc. /DESold out | February 01, 2022 | 0 | 0.0% |
| Adamas Pharmaceuticals IncSold out | January 26, 2022 | 0 | 0.0% |
| AVENUE THERAPEUTICS, INC. | February 12, 2021 | 9 | 11.0% |
| Cardiff Oncology, Inc. | February 12, 2021 | 9 | 11.0% |
| EDAP TMS SA | February 12, 2021 | 9 | 11.0% |
| Fortress Biotech, Inc. | February 12, 2021 | 9 | 11.0% |
| Gemini Therapeutics, Inc. /DE | February 12, 2021 | 9 | 11.0% |
View Opaleye Management Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-05-10 |
| 4 | 2024-04-25 |
| 4 | 2024-04-24 |
| 4 | 2024-04-19 |
| SC 13G/A | 2024-04-09 |
| SC 13G | 2024-04-08 |
| 4 | 2024-03-28 |
| 4 | 2024-03-22 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Opaleye Management Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.